MXCT

MaxCyte, Inc.

$1.13

-13.08%
SectorHealthcareIndustryMedical DevicesCountryUnited States

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.

Source: Yahoo Finance
AI summary

Price & performance

1M+11.9%
3M-6.6%
YTD-27.1%
1Y-23.1%
52-week range—
Beta1.35
Full chart and returns against a benchmark

Q-Score

44/ 100

Quality against peers; 50 is the peer median.

Growth37
Risk51
Performance41
Valuation50
Profitability46
Leverage64
Sentiment40
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$21M-5.7%
Net income-$44.6M
Net margin-213.0%-28.2 pts
Historical fundamentals

Red flags in filings

1active red flag
Exchange listing noticeJun 16, 2026
Filings, findings and the timeline

Revenue exposure

36%of revenue from outside the US
United States64%
Non Us36%
Largest customer26%
Regions, segments, customers and suppliers

Valuation

MXCTIndustryP/E—29.61P/S6.193.49EV/EBITDA—18.38P/B0.733.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 10next report, before the open
EPS estimate$-0.08
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate